IACS-13909 is a potent and specific allosteric inhibitor of SHP2, suppressing the signaling of RTK/MAPK pathway. IACS-13909 potently impedes the proliferation of tumors with a broad spectrum of RTKs as the oncogenic driver. Importantly, in NSCLC models with acquired resistance to Osimertinib, IACS-13909 administered as a single agent or in combination with Osimertinib potently reduces tumor cell proliferation in vitro and in vivo, which provide preclinical evidence for using a SHP2 inhibitor as a therapeutic strategy in acquired EGFR inhibitor-resistant NSCLC.

KEYWORDS: IACS-13909 hydrochloride | Supplier | SHP2 inhibitor | IACS13909 | IACS 13909 | CT-IACS909 | CAS [N.A.] | [2160546-07-4] | Non Selective (Tyrosine specific phosphomonoesters) | SHP | Inhibitor | Enzymes